J CATES: Open Payments
NPI 1760543714 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,499 in 127 payments from 12 companies in 2025. Trend: 2023 $2,021 · 2024 $2,451 · 2025 $2,499
Food & beverage: $2,499
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 34 | $742 |
| Alkermes, Inc. | 24 | $379 |
| Teva Pharmaceuticals USA, Inc. | 16 | $295 |
| Axsome Therapeutics, Inc. | 11 | $268 |
| Indivior Inc. | 13 | $220 |
| Neurocrine BioSciences, Inc. | 10 | $216 |
| Otsuka America Pharmaceutical, Inc. | 6 | $109 |
| Braeburn Inc. | 3 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
Products named: INVEGA SUSTENNA, ARISTADA, UZEDY, Auvelity, SUBLOCADE, INGREZZA, SPRAVATO, BRIXADI.
Industry payments across OK — which companies pay providers there.
